Pancreatic ductal adenocarcinoma (PDAC) with anaplastic features is a rare and highly aggressive subtype with an extremely poor prognosis. However, the molecular mechanisms underlying anaplastic transformation remain poorly understood. To characterize the anaplastic transformation molecular landscape, we analyzed genom...
Akimasa Hayashi, Shota Sasagawa, Takahiro Shibayama et al.· Journal of Pathology· 0 citations
Beyond direct epithelial effects, sympathetic nerves promote pancreatitis and PDAC by co-opting myofibroblasts and myCAFs as disease amplifiers, highlighting CAF subtype–specific stromal interactions as putative therapeutic targets.
Jérémy Nigri, Wen-Jun Lan, M.-L. Fung et al.· Cancer Research· 0 citations
Multiple circulating tumor DNA (ctDNA) platforms are available for KRAS mutation detection in pancreatic ductal adenocarcinoma (PDAC), including broad next-generation sequencing (NGS) and targeted quantitative polymerase chain reaction (qPCR) assays, yet comparisons of performance and concordance are limited. We...
Jennifer Guo, Michael S. May, Michael F. Berger et al.· Cancer Research· 0 citations
Pancreatic cancer (PC) is largely refractory to immune checkpoint blockade (ICB), although homologous recombination-deficient (HRD) tumors may derive benefit. In the POLAR trial of maintenance pembrolizumab plus olaparib after platinum-based chemotherapy for metastatic PC, responses remained heterogeneous. To define de...
M. Hilmi, J. Schoenfeld, Wilson H. McKerrow et al.· bioRxiv· 0 citations
KRAS G12D is a prevalent oncogenic driver in PDAC, which has a high unmet need due to few effective targeted therapies. Setidegrasib, a novel KRAS G12D-targeted protein degrader, eliminates the oncogenic driver to suppress downstream signaling and induce tumor cell death. Early clinical activity was reported in a...
W. Park, S. Kadam, A. Kasi et al.· Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.